Literature DB >> 12592082

Bexarotene is a new treatment option for lymphomatoid papulosis.

Richard A Krathen1, Staci Ward, Madeleine Duvic.   

Abstract

BACKGROUND: Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma.
OBJECTIVE: To determine whether bexarotene is effective in treating LyP.
METHODS: Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene.
RESULTS: A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients.
CONCLUSIONS: Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12592082     DOI: 10.1159/000068451

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  5 in total

1.  Donor-derived lymphomatoid papulosis in a stem-cell transplantation recipient.

Authors:  Brendan J Camp; Klaus J Busam; Isaac Brownell; Guenther Koehne; Cyrus Hedvat; Melissa P Pulitzer
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

2.  Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations.

Authors:  Neha Mehta; Alan S Wayne; Youn H Kim; Gregory A Hale; Carlos S Alvarado; Patricia Myskowski; Elaine S Jaffe; Klaus J Busam; Melissa Pulitzer; Jeffrey Zwerner; Steven Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-10-15

Review 3.  Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides.

Authors:  Meenal Kheterpal; Neha Mehta-Shah; Pooja Virmani; Patricia L Myskowski; Alison Moskowitz; Steven M Horwitz
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

Review 4.  EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  Werner Kempf; Katrin Pfaltz; Maarten H Vermeer; Antonio Cozzio; Pablo L Ortiz-Romero; Martine Bagot; Elise Olsen; Youn H Kim; Reinhard Dummer; Nicola Pimpinelli; Sean Whittaker; Emmilia Hodak; Lorenzo Cerroni; Emilio Berti; Steve Horwitz; H Miles Prince; Joan Guitart; Teresa Estrach; José A Sanches; Madeleine Duvic; Annamari Ranki; Brigitte Dreno; Sonja Ostheeren-Michaelis; Robert Knobler; Gary Wood; Rein Willemze
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

5.  Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.

Authors:  Madeleine Duvic; Jenny Vu
Journal:  Biologics       Date:  2007-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.